Clinical Trial Update: A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes that Nanjing Leads Biolabs Co., Ltd. is recruiting for a Phase 1/2 study of LBL-024 as a monotherapy or in combination for trip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• LBL-024

Snippet

Sponsor: Nanjing Leads Biolabs Co.,Ltd | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING